Lee Ainslie Vertex Pharmaceuticals Inc Transaction History

Maverick Capital LTD

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$343.0 - $410.68 $221,235 - $264,888	-645 Reduced 44.27%	812 $330,000
Q3 2023 Nov 14, 2023	BUY	$338.18 - $362.46 $492,728 - $528,104	1,457 New	1,457 $506,000
Q4 2021 Feb 14, 2022	SELL	$177.01 - $223.45 $3.2 Million - $4.03 Million	-18,052 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$181.39 - $202.99 $3.27 Million - $3.66 Million	18,052 New	18,052 $3.27 Million
Q2 2021 Aug 16, 2021	SELL	$187.49 - $221.1 $1.17 Million - $1.38 Million	-6,254 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$207.02 - $241.31 $1.29 Million - $1.51 Million	6,254 New	6,254 $1.34 Million
Q2 2020 Aug 14, 2020	SELL	$225.48 - $295.8 $103,720 - $136,068	-460 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$199.77 - $247.81 $91,894 - $113,992	460 New	460 $109,000

1,723

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $116B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Maverick Capital LTD, based on Form 13F filings with the SEC.

Stay updated on Maverick Capital LTD and Lee Ainslie with notifications on news.